United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Cumberland Partners Ltd

Cumberland Partners Ltd reduced its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 5.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,900 shares of the biotechnology company’s stock after selling 100 shares during the quarter. Cumberland Partners Ltd’s holdings in United Therapeutics were worth $670,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Newbridge Financial Services Group Inc. acquired a new stake in United Therapeutics in the fourth quarter valued at $25,000. Brooklyn Investment Group purchased a new position in shares of United Therapeutics in the 3rd quarter valued at about $33,000. Capital Performance Advisors LLP acquired a new stake in shares of United Therapeutics in the third quarter valued at about $82,000. MassMutual Private Wealth & Trust FSB lifted its stake in shares of United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 58 shares during the period. Finally, Values First Advisors Inc. purchased a new stake in United Therapeutics during the third quarter worth about $90,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Louis W. Sullivan sold 26,209 shares of the company’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the completion of the transaction, the director now owns 5,051 shares of the company’s stock, valued at $1,885,134.22. This represents a 83.84 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Paul A. Mahon sold 7,700 shares of the stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $374.37, for a total transaction of $2,882,649.00. Following the transaction, the executive vice president now owns 36,710 shares in the company, valued at approximately $13,743,122.70. The trade was a 17.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 124,164 shares of company stock valued at $45,398,793 over the last 90 days. Insiders own 11.90% of the company’s stock.

United Therapeutics Trading Down 3.5 %

NASDAQ:UTHR opened at $367.36 on Friday. United Therapeutics Co. has a 12-month low of $214.52 and a 12-month high of $417.82. The firm has a market cap of $16.40 billion, a price-to-earnings ratio of 16.13, a price-to-earnings-growth ratio of 0.97 and a beta of 0.57. The company’s 50-day moving average is $362.70 and its two-hundred day moving average is $359.94.

Wall Street Analyst Weigh In

UTHR has been the subject of a number of research reports. The Goldman Sachs Group lifted their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. Argus raised their price objective on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Oppenheimer boosted their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Finally, UBS Group lifted their price target on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $382.08.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.